Jenni Kyyriainen
Overview
Explore the profile of Jenni Kyyriainen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kyyriainen J, Andrade P, Ndode-Ekane X, Manninen E, Hamalainen E, Rauramaa T, et al.
Epilepsy Res
. 2024 Jan;
200:107301.
PMID: 38244466
Objective: To assess the prevalence of brain abscesses as a confounding factor for the diagnosis of post-traumatic epilepsy (PTE) in a rat model of lateral fluid-percussion-induced (FPI) traumatic brain injury...
2.
Kyyriainen J, Andrade P, Hamalainen E, Pitkanen A
Neurotrauma Rep
. 2023 Jun;
4(1):384-395.
PMID: 37350791
We report on a case study of a Wistar rat that was investigated in detail because it exhibited no N3 sleep in electroencephalography (EEG) after lateral fluid-percussion injury (FPI)-induced traumatic...
3.
Kyyriainen J, Kajevu N, Banuelos I, Lara L, Lipponen A, Balosso S, et al.
Int J Mol Sci
. 2021 Oct;
22(19).
PMID: 34638900
We assessed the effect of antioxidant therapy using the Food and Drug Administration-approved respiratory drug -acetylcysteine (NAC) or sulforaphane (SFN) as monotherapies or duotherapy in vitro in neuron-BV2 microglial co-cultures...
4.
Kyyriainen J, Tapiala J, Lipponen A, Ndode-Ekane X, Pitkanen A
Neurosci Lett
. 2020 May;
729:134935.
PMID: 32360936
Binding of urokinase-type plasminogen activator receptor (uPAR) to its ligand uPA or to its plasma membrane partner, platelet-derived growth factor receptor β (PDGFRβ), promotes neuroprotection, cell proliferation, and angiogenesis. Following...
5.
Pitkanen A, Paananen T, Kyyriainen J, Gupta S, Heiskanen M, Vuokila N, et al.
Epilepsy Behav
. 2020 Apr;
121(Pt B):107080.
PMID: 32317161
A biomarker is a characteristic that can be objectively measured as an indicator of normal biologic processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker...
6.
Schweser F, Kyyriainen J, Preda M, Pitkanen A, Toffolo K, Poulsen A, et al.
Neuroimage
. 2019 Jun;
200:250-258.
PMID: 31201986
A key event in the pathophysiology of traumatic brain injury (TBI) is the influx of substantial amounts of Ca into neurons, particularly in the thalamus. Detection of this calcium influx...
7.
Kyyriainen J, Bolkvadze T, Koivisto H, Lipponen A, Perez L, Ndode-Ekane X, et al.
Epilepsy Res
. 2019 Mar;
151:67-74.
PMID: 30836238
Extracellular proteolysis initiated by the binding of urokinase-type plasminogen activator (uPA) to its receptor (uPAR) regulates the development of inhibitory neuronal circuits in the cerebral cortex and tissue remodeling after...
8.
Kyyriainen J, Ndode-Ekane X, Pitkanen A
Glia
. 2016 Oct;
65(2):322-341.
PMID: 27778377
Platelet-derived growth factor receptor β (PDGFRβ) is upregulated after brain injury and its depletion results in the blood-brain barrier (BBB) damage. We investigated the time-window and localization of PDGFRβ expression...
9.
Pitkanen A, Huusko N, Ndode-Ekane X, Kyyriainen J, Lipponen A, Lipsanen A, et al.
Neurobiol Dis
. 2014 Jun;
72 Pt B:224-32.
PMID: 24912075
Disease modification of epilepsy refers to the alleviation of epileptogenesis or comorbidities after genetic or acquired epileptogenic brain insults. There are currently 30 proof-of-concept experimental pharmacologic studies that have demonstrated...